EXTON, Pa., April 10 /PRNewswire/ -- On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva (efalizumab, marketed by Genentech/Roche and Xoma) from the US market. The withdrawal comes after recent post-marketing reports of PML associated with Raptiva treatment.
BioTrends will field its fourth annual TreatmentTrends(TM): Psoriasis survey on April 13th with a special section dedicated to the impact of the Raptiva withdrawal. The on-line survey will be completed by 150 clinical dermatologists and is structured to assess treatment prevalence and brand use for topical, oral, and biologic agents. A comprehensive attribute analysis is provided for each class to indicate areas of unmet need and market share projections for the next six months. In addition, awareness and interest in products in late stage development, such as Centocor's STELARA (ustekinumab) and Abbott's ABT-874 is assessed. The report will be published in early May.
A second report offered by BioTrends, ChartTrends(TM): Biologics in Psoriasis, is a report that is based on actual patient level audit data collected through a proprietary audit tool. In this report, 1000 patients who are currently being treated with biologic agents will be reviewed to analyze the treatment algorithm that culminates in the use of biologic agents, patient demographics/co-morbidities associated with specific biologic brand use, product switching incidence and rationale, and concomitant medications. A special section focused on switches from Raptiva will be included to understand if these patients migrate to other biologic brands or are discontinued altogether from biologic therapy. This report will be published in early June.
According to last year's TreatmentTrends(TM): Psoriasis report, market share for Raptiva had steadily declined since 2006 and only 44% of the dermatologists surveyed were using the product in their practices in April 2008. Amgen/Wyeth's Enbrel and Abbott's Humira, the most frequently prescribed biologics in psoriasis, were rated significantly higher than Raptiva on nearly all of the most important attributes. However, Raptiva held a competitive advantage over all biologic competitors on its efficacy in palmo-plantar psoriasis.
About BioTrends Research Group, Inc.
BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
|SOURCE BioTrends Research Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved